FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039812143> ?p ?o ?g. }

• W2039812143 endingPage "P46" @default.
• W2039812143 startingPage "P46" @default.
• W2039812143 abstract "More than 70,000 people are admitted to US hospitals each year after major burn injury. Achieving adequate pain control in these patients remains a substantial clinical challenge. Even with the use of “best practice” medications, additional methods of decreasing burn pain are urgently needed. We performed a pilot multicenter, genotype-guided, randomized, double-blind, placebo-controlled trial of propranolol to reduce pain in the initial weeks after major thermal burn injury. Eligible and consenting patients admitted to network burn centers within 72 hours of acute thermal burn injury were genotyped at rs4818. After two days of initial interview assessments, genotype eligible patients were randomized to 120 mg twice daily of propranolol vs. placebo. Study drug was continued until three weeks after hospital discharge. The primary outcome measure was daily pain score (0 – 10 numeric rating pain score) recorded by the patient during the first 19 days after study drug initiation. Study feasibility was evaluated via consent and protocol completion rates, while study acceptability was assessed via qualitative analyses. Efficacy evaluations were performed to generate estimates of potential therapeutic benefit using mixed effects models with random intercepts to account for subject effects and the correlation among repeated measurements within a subject. To date, 73% (44/60) of eligible patients consented to complete initial interview evaluation and genotyping for the study. Seventy nine percent (34/43) were eligible based on genotype and were subsequently enrolled in the RCT. Eighty two percent (28/34) both tolerated study drug and underwent primary outcome assessments. The great majority (91%) of study participants agreed with the statement, “Had I know in advance what participating would be like for me, I still would have agreed.” Pilot enrollment (n=40 completing trial) will conclude by early 2011; estimates of potential therapeutic benefit based on efficacy analyses will be presented. More than 70,000 people are admitted to US hospitals each year after major burn injury. Achieving adequate pain control in these patients remains a substantial clinical challenge. Even with the use of “best practice” medications, additional methods of decreasing burn pain are urgently needed. We performed a pilot multicenter, genotype-guided, randomized, double-blind, placebo-controlled trial of propranolol to reduce pain in the initial weeks after major thermal burn injury. Eligible and consenting patients admitted to network burn centers within 72 hours of acute thermal burn injury were genotyped at rs4818. After two days of initial interview assessments, genotype eligible patients were randomized to 120 mg twice daily of propranolol vs. placebo. Study drug was continued until three weeks after hospital discharge. The primary outcome measure was daily pain score (0 – 10 numeric rating pain score) recorded by the patient during the first 19 days after study drug initiation. Study feasibility was evaluated via consent and protocol completion rates, while study acceptability was assessed via qualitative analyses. Efficacy evaluations were performed to generate estimates of potential therapeutic benefit using mixed effects models with random intercepts to account for subject effects and the correlation among repeated measurements within a subject. To date, 73% (44/60) of eligible patients consented to complete initial interview evaluation and genotyping for the study. Seventy nine percent (34/43) were eligible based on genotype and were subsequently enrolled in the RCT. Eighty two percent (28/34) both tolerated study drug and underwent primary outcome assessments. The great majority (91%) of study participants agreed with the statement, “Had I know in advance what participating would be like for me, I still would have agreed.” Pilot enrollment (n=40 completing trial) will conclude by early 2011; estimates of potential therapeutic benefit based on efficacy analyses will be presented." @default.
• W2039812143 created "2016-06-24" @default.
• W2039812143 creator A5008683790 @default.
• W2039812143 creator A5031745550 @default.
• W2039812143 creator A5043166735 @default.
• W2039812143 creator A5047524682 @default.
• W2039812143 creator A5050366153 @default.
• W2039812143 creator A5055323138 @default.
• W2039812143 creator A5056343888 @default.
• W2039812143 creator A5056468592 @default.
• W2039812143 creator A5059483883 @default.
• W2039812143 creator A5061618489 @default.
• W2039812143 creator A5080313559 @default.
• W2039812143 creator A5086596530 @default.
• W2039812143 date "2011-04-01" @default.
• W2039812143 modified "2023-09-27" @default.
• W2039812143 title "Pilot multicenter, genotype-based, randomized, double-blind, placebo-controlled trial of propranolol to reduce initial pain symptoms in patients with major burn injury" @default.
• W2039812143 doi "https://doi.org/10.1016/j.jpain.2011.02.186" @default.
• W2039812143 hasPublicationYear "2011" @default.
• W2039812143 type Work @default.
• W2039812143 sameAs 2039812143 @default.
• W2039812143 citedByCount "0" @default.
• W2039812143 crossrefType "journal-article" @default.
• W2039812143 hasAuthorship W2039812143A5008683790 @default.
• W2039812143 hasAuthorship W2039812143A5031745550 @default.
• W2039812143 hasAuthorship W2039812143A5043166735 @default.
• W2039812143 hasAuthorship W2039812143A5047524682 @default.
• W2039812143 hasAuthorship W2039812143A5050366153 @default.
• W2039812143 hasAuthorship W2039812143A5055323138 @default.
• W2039812143 hasAuthorship W2039812143A5056343888 @default.
• W2039812143 hasAuthorship W2039812143A5056468592 @default.
• W2039812143 hasAuthorship W2039812143A5059483883 @default.
• W2039812143 hasAuthorship W2039812143A5061618489 @default.
• W2039812143 hasAuthorship W2039812143A5080313559 @default.
• W2039812143 hasAuthorship W2039812143A5086596530 @default.
• W2039812143 hasBestOaLocation W20398121431 @default.
• W2039812143 hasConcept C126322002 @default.
• W2039812143 hasConcept C141071460 @default.
• W2039812143 hasConcept C142724271 @default.
• W2039812143 hasConcept C168563851 @default.
• W2039812143 hasConcept C1862650 @default.
• W2039812143 hasConcept C204787440 @default.
• W2039812143 hasConcept C27081682 @default.
• W2039812143 hasConcept C2993242423 @default.
• W2039812143 hasConcept C42219234 @default.
• W2039812143 hasConcept C535046627 @default.
• W2039812143 hasConcept C71924100 @default.
• W2039812143 hasConceptScore W2039812143C126322002 @default.
• W2039812143 hasConceptScore W2039812143C141071460 @default.
• W2039812143 hasConceptScore W2039812143C142724271 @default.
• W2039812143 hasConceptScore W2039812143C168563851 @default.
• W2039812143 hasConceptScore W2039812143C1862650 @default.
• W2039812143 hasConceptScore W2039812143C204787440 @default.
• W2039812143 hasConceptScore W2039812143C27081682 @default.
• W2039812143 hasConceptScore W2039812143C2993242423 @default.
• W2039812143 hasConceptScore W2039812143C42219234 @default.
• W2039812143 hasConceptScore W2039812143C535046627 @default.
• W2039812143 hasConceptScore W2039812143C71924100 @default.
• W2039812143 hasIssue "4" @default.
• W2039812143 hasLocation W20398121431 @default.
• W2039812143 hasOpenAccess W2039812143 @default.
• W2039812143 hasPrimaryLocation W20398121431 @default.
• W2039812143 hasRelatedWork W195854409 @default.
• W2039812143 hasRelatedWork W1983403674 @default.
• W2039812143 hasRelatedWork W1984226278 @default.
• W2039812143 hasRelatedWork W2009588589 @default.
• W2039812143 hasRelatedWork W3159250744 @default.
• W2039812143 hasRelatedWork W4233016836 @default.
• W2039812143 hasRelatedWork W4256514411 @default.
• W2039812143 hasRelatedWork W4292236216 @default.
• W2039812143 hasRelatedWork W4312225894 @default.
• W2039812143 hasRelatedWork W2083697902 @default.
• W2039812143 hasVolume "12" @default.
• W2039812143 isParatext "false" @default.
• W2039812143 isRetracted "false" @default.
• W2039812143 magId "2039812143" @default.
• W2039812143 workType "article" @default.